Reporter : Xue Shasha
Publisher : The Paper
Ref : https://www.thepaper.cn/newsDetail_forward_7019798
Extract Translation, editing : Gan Yung Chyan
/ KUCINTA SETIA
Image courtesy : Yahoo!
The term "three medicines and three prescriptions" for novel coronavirus pneumonia (covid, in short) originated from a press conference held by the State Council Information Office on 23 March 2020, where "three medicines" refers to Lianhua Qingwen (连花清瘟) Capsules (Granules), Jinhua Qinggan (金花清感) Granules and Xuebijing (血必净) Injection.
Recently, these three medicines have become the first batch of medicines approved for treatment of covid symptoms in China. Once the relevant announcement was issued, these products immediately attracted public attention in Communist China.
This is not the first time the three medicines have received attention. As early as in early February, they were all included in the "Novel Coronavirus Pneumonia Diagnosis and Treatment Program" (Trial Version 4). Since then, they have appeared in multiple versions of the program and clinical diagnosis and treatment of patients with covid.
The Lianhua Qingwen was developed for the treatment of SARS, and the Jinhua Qinggan Granules were developed in response to H1N1 influenza.
In the prevention and control of the covid pandemic, the "three medicines" played an important role, and as a result, their usage has become tight, sales increased significantly, and even shortages occurred.
An expert in traditional Chinese medicine said in an interview with The Paper (www.thepaper.cn) on 17 April 2020 that although the three medicines can treat covid, the corresponding symptoms are different, and they should be treated as symptomatically. Citizens who have no symptoms and are not infected with covid should not take these drugs, nor can they "prevent" covid by taking these three "treatment" drugs. Three new drugs have been approved for symptoms treatment of covid, which will provide a boost for Chinese medicine to go global.
However, if Chinese medicine is to be truly internationally recognized, there is still a long way to go.
Three Chinese patent medicines approved to treat symptoms of covid
The relevant approval documents issued by the State Drug Administration respectively state:
Approval of Lianhua Qingwen Capsules (Granules) Instructions
"Routine treatment of covid, can be used for fever, cough and fatigue" [Usage and Dosage] "Light covid and ordinary treatment course 7-10 days. "
Approval of Xuebijing Injection Instructions [Functional Indications]
The injection fluid "can be used for severe and critical covid systemic inflammatory response syndrome or / and multiple organ failure."
[Usage and Dosage] "Usage in treatment of covid: 100ml diluted with 0.9% sodium chloride injection 250ml, twice a day. "
In addition to the original approved content, the "Functional Indications" item in the approved Jinhua Qinggan Granules was added "In the routine treatment of covid, it can be used for fever, cough, and fatigue".
[Usage and Dosage] "Usage in treatment of light and ordinary symptoms of covid: 1 to 2 bags at a time, 3 times a day. The course of treatment is 5 to 7 days."
The Paper inquiry found that the functions of the three Chinese patent medicines all include "clearing heat and detoxification", which is suitable for fever symptoms. Among them, Lianhua Qingwen Capsule also treats "coldness, muscle soreness, nasal congestion, runny nose, cough", etc .; Xuebijing Injection also treats wheezing, palpitations, infection-induced systemic inflammation, etc .; the treatment functions of Jinhua Qinggan Granules are for "Red and sore throat, stuffy nose, runny nose, thirst" and so on.
Information from the State Administration of Drug Administration shows that Lianhua Qingwen Capsules, Granules and Tablets belong to Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as: Yiling Pharmaceutical) and its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. Xuebijing injection fluid is produced by Tianjin Hongri Pharmaceutical Co., Ltd. (hereinafter: Hongri Pharmaceutical); Jinhua Qinggan Granule is produced by Juxiechang (Beijing), a subsidiary of Beijing Yushengtang Sinopharm Holding Co., Ltd. It is an exclusive product of the pharmaceutical industry.
The Paper noted that after the approved news was announced, as of 17 April 2020, Yiling Pharmaceutical Co. Ltd. and Hongri Pharmaceutical Co. Ltd., which are listed companies, had experienced three consecutive days of daily medicine enquiries.
Lianhua Qingwen "born because of SARS"
Lianhua Qingwen was developed for the treatment of SARS.
A department head of Yiling Pharmaceutical Company told The Paper on 15 April 2020 that the SARS epidemic broke out in 2003, and Wu Yiling, an academician of the Chinese Academy of Engineering and founder of Yiling Pharmaceuticals, started research and development of symptomatic new drugs.
According to the person in charge, Lianhua Qingwen Capsules and Granules gathered the three dynasty prescriptions of Zhang Zhongjing's "Ma Xing Shi Gan Tang" in the Han Dynasty, "Rhubarb" which can be used to cure epidemic diseases in Wu Dynasty in the Ming Dynasty, and "Yinqiao San" in Wu Jutong in the Qing Dynasty. It is developed by combining the effective traditional Chinese medicine found in modern scientific research with anti-virus, anti-inflammatory, cough, phlegm and immunity enhancement. Related experiments confirmed that Lianhua Qingwen Capsules has an inhibitory effect on SARS virus. Soon afterwards, Lianhua Qingwen Capsules entered the green channel for rapid approval of new anti-SARS drugs.
After the SARS epidemic ended, Lianhua Qingwen turned to the battlefield against H1N1 influenza.
The person in charge said that in the view of Chinese medicine, influenza and "SARS" belong to the category of "external fever", which is what the Chinese medicine called "the plague". Experiments by the Chinese Academy of Chinese Medical Sciences have confirmed that Lianhua Qingwen can inhibit influenza virus H3N2, parainfluenza virus type I, respiratory syncytial virus, and adenovirus.
In May 2004, Lianhua Qingwen Capsule passed the review of the State Drug Administration and other departments, obtained a new drug certificate and production approval, and became a new member of China's anti-influenza drugs.
The Paper found that Lianhua Qingwen Capsules (granules) has been included in the national diagnosis and treatment program more than 20 times as a recommended drug, including "Diagnosis and Treatment Program for Novel Coronavirus Pneumonia" (Trial Version 4 to 7) Version).
On 31 March 2020, Lianhua Qingwen Capsules (granules) is approved by the Ministry of Health of Thailand for herbal medicine registration and suitable for sales at Thai pharmacies.
Lianhua Qingwen Capsules have also been registered in Hong Kong, Macau, Brazil, Indonesia and Canada and have been approved for marketing.
Similar to Lianhua Qingwen, Jinhua Qinggan granules are also "born due to disease".
According to Caixin.com, in April 2009, influenza A H1N1 from North America spread. In June, the Beijing Municipal Government launched a scientific and technological breakthrough in the treatment of the flu with traditional Chinese medicine. In December of that year, the Information Office of the Beijing Municipal Government announced that "an effective method for the treatment of influenza A H1N1 influenza" Jinhua Qinggan Recipe "", then, the prescription evolved into today's "Jinhua Qinggan Granules."
"Three medicines" sales may grow again
Because of the extraordinary performance in the clinical treatment of covid, coupled with the affirmation of experts, these three drugs have an effect on the treatment of covid, so they have become "tight drugs" this year.
According to the aforementioned person in charge of the Yiling pharmaceutical department, in order to ensure supply, the company has adjusted its production plan urgently according to market demand since late January, and used all production lines for 24 hours to produce Lianhua Qingwen products. The maximum daily production capacity is 50 million capsules. , More than 2 million bags of granules, other products temporarily rely on the company's finished product inventory and commercial channel inventory to meet market supply.
The person in charge said that after nearly 40 days of "production rush action", the current shortage of terminals in the Lianhua Qingwen market has eased. The current main bottleneck in production capacity is the extraction capacity of medicinal materials. The follow-up company plans to invest in a production base in Hengshui City, Hebei Province. The first phase will give priority to building an extraction workshop to alleviate the company's current bottleneck in extraction capacity.
In addition to being approved for the addition of covid symptoms treatment, the State Drug Administration issued an announcement on 8 April 2020 that in order to meet the needs of covid prevention and control, Jinhua Qinggan granules will be converted from prescription drugs to class A over-the-counter drugs.
This means that Jinhua Qinggan granules can be entered into pharmacies for retail like Lianhua Qingwen capsules. Lianhua Qingwen granules (tablets) and Xuebijing are prescription drugs, which need to be purchased with a prescription or doctor's order.
Expert: There is still a long way to go for Chinese medicine to be recognized internationally
Liu Baoyan, former executive vice president of the Chinese Academy of Chinese Medical Sciences and director of the Chinese Medicine Data Center, told The Paper on 17 April 2020 that during the epidemic, he and Wuhan first-line researchers collaborated to take patients with covid in Wuchang District as the sample and rely on the Internet to issue covid medication. The data shows that among the medicines taken by patients, Chinese patent medicines take the first place, accounting for 35.99%.
Liu Baoyan introduced that Jinhua Qinggan granules can treat patients with fever faster than other drugs, which is mainly suitable for early and mild patients. Lianhua Qingwen can also treat cough and relieve lung inflammation. The injection fluid can also protect the patient's organs from damage and can be used by severe and critically ill patients.
"It is a three-way drug. Any medicine has indications. This is especially true of traditional Chinese medicine. Different people may have different reactions with the same medicine." Liu Baoyan said that although all three medicines can treat covid, they also need to try to use symptomatic medicine as much as possible.
In a previous interview, The Paper reporter also learned that some citizens did not contract covid, but thought that drugs such as Lianhua Qingwen could prevent infection, so they bought it for themselves.
In this regard, Liu Baoyan particularly reminded that citizens who have no symptoms and are not infected with covid should not take these drugs, nor can they "prevent" covid by taking three "treatment" drugs.
"If you take these medicines without getting sick, it will damage the stomach and the body's yang."
He suggested that if the citizens are worried about infection, they can take medicines that strengthen the body and strengthen their resistance according to their physical characteristics, such as spleen and stomach. He stressed it is necessary for symptomatic use of drugs to regulate the spleen and stomach. In addition, sleeping on time, eating regularly, and exercising regularly can all enhance the body's immunity against viruses. "You don't have to take the medicine if you are not infected."
Covid is spreading in many countries around the world. These three drugs have been approved for new indications for covid, which also provides a thrust for Chinese medicine to go global. In Liu Baoyan's view, there is still a long way to go before Chinese medicine can be truly recognized internationally. He said frankly that some countries have strict approvals for medicines. If they want to enter the shelves of medicines in other countries, they must first obtain approval. At the same time, foreign medicines are mostly single-component medicines, while traditional Chinese medicines are multi-component medicines.
Foreigners generally worry about the side effects of traditional Chinese medicines. In addition, the citizens of some countries have relatively large deviations in the understanding of Chinese medicine, which has also caused Chinese medicine to be blocked in the world.
Further Refs:
https://www.biospectrumasia.com/news/30/15694/yiling-pharmacy-receives-approval-for-herbal-medicine-in-thailand.html
https://news.yahoo.com/lianhua-qingwen-capsule-granule-approved-215500996.html
Publisher : The Paper
Ref : https://www.thepaper.cn/newsDetail_forward_7019798
Extract Translation, editing : Gan Yung Chyan
/ KUCINTA SETIA
Image courtesy : Yahoo!
The term "three medicines and three prescriptions" for novel coronavirus pneumonia (covid, in short) originated from a press conference held by the State Council Information Office on 23 March 2020, where "three medicines" refers to Lianhua Qingwen (连花清瘟) Capsules (Granules), Jinhua Qinggan (金花清感) Granules and Xuebijing (血必净) Injection.
Recently, these three medicines have become the first batch of medicines approved for treatment of covid symptoms in China. Once the relevant announcement was issued, these products immediately attracted public attention in Communist China.
This is not the first time the three medicines have received attention. As early as in early February, they were all included in the "Novel Coronavirus Pneumonia Diagnosis and Treatment Program" (Trial Version 4). Since then, they have appeared in multiple versions of the program and clinical diagnosis and treatment of patients with covid.
The Lianhua Qingwen was developed for the treatment of SARS, and the Jinhua Qinggan Granules were developed in response to H1N1 influenza.
In the prevention and control of the covid pandemic, the "three medicines" played an important role, and as a result, their usage has become tight, sales increased significantly, and even shortages occurred.
An expert in traditional Chinese medicine said in an interview with The Paper (www.thepaper.cn) on 17 April 2020 that although the three medicines can treat covid, the corresponding symptoms are different, and they should be treated as symptomatically. Citizens who have no symptoms and are not infected with covid should not take these drugs, nor can they "prevent" covid by taking these three "treatment" drugs. Three new drugs have been approved for symptoms treatment of covid, which will provide a boost for Chinese medicine to go global.
However, if Chinese medicine is to be truly internationally recognized, there is still a long way to go.
Three Chinese patent medicines approved to treat symptoms of covid
The relevant approval documents issued by the State Drug Administration respectively state:
Approval of Lianhua Qingwen Capsules (Granules) Instructions
"Routine treatment of covid, can be used for fever, cough and fatigue" [Usage and Dosage] "Light covid and ordinary treatment course 7-10 days. "
Approval of Xuebijing Injection Instructions [Functional Indications]
The injection fluid "can be used for severe and critical covid systemic inflammatory response syndrome or / and multiple organ failure."
[Usage and Dosage] "Usage in treatment of covid: 100ml diluted with 0.9% sodium chloride injection 250ml, twice a day. "
In addition to the original approved content, the "Functional Indications" item in the approved Jinhua Qinggan Granules was added "In the routine treatment of covid, it can be used for fever, cough, and fatigue".
[Usage and Dosage] "Usage in treatment of light and ordinary symptoms of covid: 1 to 2 bags at a time, 3 times a day. The course of treatment is 5 to 7 days."
The Paper inquiry found that the functions of the three Chinese patent medicines all include "clearing heat and detoxification", which is suitable for fever symptoms. Among them, Lianhua Qingwen Capsule also treats "coldness, muscle soreness, nasal congestion, runny nose, cough", etc .; Xuebijing Injection also treats wheezing, palpitations, infection-induced systemic inflammation, etc .; the treatment functions of Jinhua Qinggan Granules are for "Red and sore throat, stuffy nose, runny nose, thirst" and so on.
Information from the State Administration of Drug Administration shows that Lianhua Qingwen Capsules, Granules and Tablets belong to Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as: Yiling Pharmaceutical) and its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. Xuebijing injection fluid is produced by Tianjin Hongri Pharmaceutical Co., Ltd. (hereinafter: Hongri Pharmaceutical); Jinhua Qinggan Granule is produced by Juxiechang (Beijing), a subsidiary of Beijing Yushengtang Sinopharm Holding Co., Ltd. It is an exclusive product of the pharmaceutical industry.
The Paper noted that after the approved news was announced, as of 17 April 2020, Yiling Pharmaceutical Co. Ltd. and Hongri Pharmaceutical Co. Ltd., which are listed companies, had experienced three consecutive days of daily medicine enquiries.
Lianhua Qingwen "born because of SARS"
Lianhua Qingwen was developed for the treatment of SARS.
A department head of Yiling Pharmaceutical Company told The Paper on 15 April 2020 that the SARS epidemic broke out in 2003, and Wu Yiling, an academician of the Chinese Academy of Engineering and founder of Yiling Pharmaceuticals, started research and development of symptomatic new drugs.
According to the person in charge, Lianhua Qingwen Capsules and Granules gathered the three dynasty prescriptions of Zhang Zhongjing's "Ma Xing Shi Gan Tang" in the Han Dynasty, "Rhubarb" which can be used to cure epidemic diseases in Wu Dynasty in the Ming Dynasty, and "Yinqiao San" in Wu Jutong in the Qing Dynasty. It is developed by combining the effective traditional Chinese medicine found in modern scientific research with anti-virus, anti-inflammatory, cough, phlegm and immunity enhancement. Related experiments confirmed that Lianhua Qingwen Capsules has an inhibitory effect on SARS virus. Soon afterwards, Lianhua Qingwen Capsules entered the green channel for rapid approval of new anti-SARS drugs.
After the SARS epidemic ended, Lianhua Qingwen turned to the battlefield against H1N1 influenza.
The person in charge said that in the view of Chinese medicine, influenza and "SARS" belong to the category of "external fever", which is what the Chinese medicine called "the plague". Experiments by the Chinese Academy of Chinese Medical Sciences have confirmed that Lianhua Qingwen can inhibit influenza virus H3N2, parainfluenza virus type I, respiratory syncytial virus, and adenovirus.
In May 2004, Lianhua Qingwen Capsule passed the review of the State Drug Administration and other departments, obtained a new drug certificate and production approval, and became a new member of China's anti-influenza drugs.
The Paper found that Lianhua Qingwen Capsules (granules) has been included in the national diagnosis and treatment program more than 20 times as a recommended drug, including "Diagnosis and Treatment Program for Novel Coronavirus Pneumonia" (Trial Version 4 to 7) Version).
On 31 March 2020, Lianhua Qingwen Capsules (granules) is approved by the Ministry of Health of Thailand for herbal medicine registration and suitable for sales at Thai pharmacies.
Lianhua Qingwen Capsules have also been registered in Hong Kong, Macau, Brazil, Indonesia and Canada and have been approved for marketing.
Similar to Lianhua Qingwen, Jinhua Qinggan granules are also "born due to disease".
According to Caixin.com, in April 2009, influenza A H1N1 from North America spread. In June, the Beijing Municipal Government launched a scientific and technological breakthrough in the treatment of the flu with traditional Chinese medicine. In December of that year, the Information Office of the Beijing Municipal Government announced that "an effective method for the treatment of influenza A H1N1 influenza" Jinhua Qinggan Recipe "", then, the prescription evolved into today's "Jinhua Qinggan Granules."
"Three medicines" sales may grow again
Because of the extraordinary performance in the clinical treatment of covid, coupled with the affirmation of experts, these three drugs have an effect on the treatment of covid, so they have become "tight drugs" this year.
According to the aforementioned person in charge of the Yiling pharmaceutical department, in order to ensure supply, the company has adjusted its production plan urgently according to market demand since late January, and used all production lines for 24 hours to produce Lianhua Qingwen products. The maximum daily production capacity is 50 million capsules. , More than 2 million bags of granules, other products temporarily rely on the company's finished product inventory and commercial channel inventory to meet market supply.
The person in charge said that after nearly 40 days of "production rush action", the current shortage of terminals in the Lianhua Qingwen market has eased. The current main bottleneck in production capacity is the extraction capacity of medicinal materials. The follow-up company plans to invest in a production base in Hengshui City, Hebei Province. The first phase will give priority to building an extraction workshop to alleviate the company's current bottleneck in extraction capacity.
In addition to being approved for the addition of covid symptoms treatment, the State Drug Administration issued an announcement on 8 April 2020 that in order to meet the needs of covid prevention and control, Jinhua Qinggan granules will be converted from prescription drugs to class A over-the-counter drugs.
This means that Jinhua Qinggan granules can be entered into pharmacies for retail like Lianhua Qingwen capsules. Lianhua Qingwen granules (tablets) and Xuebijing are prescription drugs, which need to be purchased with a prescription or doctor's order.
Expert: There is still a long way to go for Chinese medicine to be recognized internationally
Liu Baoyan, former executive vice president of the Chinese Academy of Chinese Medical Sciences and director of the Chinese Medicine Data Center, told The Paper on 17 April 2020 that during the epidemic, he and Wuhan first-line researchers collaborated to take patients with covid in Wuchang District as the sample and rely on the Internet to issue covid medication. The data shows that among the medicines taken by patients, Chinese patent medicines take the first place, accounting for 35.99%.
Liu Baoyan introduced that Jinhua Qinggan granules can treat patients with fever faster than other drugs, which is mainly suitable for early and mild patients. Lianhua Qingwen can also treat cough and relieve lung inflammation. The injection fluid can also protect the patient's organs from damage and can be used by severe and critically ill patients.
"It is a three-way drug. Any medicine has indications. This is especially true of traditional Chinese medicine. Different people may have different reactions with the same medicine." Liu Baoyan said that although all three medicines can treat covid, they also need to try to use symptomatic medicine as much as possible.
In a previous interview, The Paper reporter also learned that some citizens did not contract covid, but thought that drugs such as Lianhua Qingwen could prevent infection, so they bought it for themselves.
In this regard, Liu Baoyan particularly reminded that citizens who have no symptoms and are not infected with covid should not take these drugs, nor can they "prevent" covid by taking three "treatment" drugs.
"If you take these medicines without getting sick, it will damage the stomach and the body's yang."
He suggested that if the citizens are worried about infection, they can take medicines that strengthen the body and strengthen their resistance according to their physical characteristics, such as spleen and stomach. He stressed it is necessary for symptomatic use of drugs to regulate the spleen and stomach. In addition, sleeping on time, eating regularly, and exercising regularly can all enhance the body's immunity against viruses. "You don't have to take the medicine if you are not infected."
Covid is spreading in many countries around the world. These three drugs have been approved for new indications for covid, which also provides a thrust for Chinese medicine to go global. In Liu Baoyan's view, there is still a long way to go before Chinese medicine can be truly recognized internationally. He said frankly that some countries have strict approvals for medicines. If they want to enter the shelves of medicines in other countries, they must first obtain approval. At the same time, foreign medicines are mostly single-component medicines, while traditional Chinese medicines are multi-component medicines.
Foreigners generally worry about the side effects of traditional Chinese medicines. In addition, the citizens of some countries have relatively large deviations in the understanding of Chinese medicine, which has also caused Chinese medicine to be blocked in the world.
Further Refs:
https://www.biospectrumasia.com/news/30/15694/yiling-pharmacy-receives-approval-for-herbal-medicine-in-thailand.html
https://news.yahoo.com/lianhua-qingwen-capsule-granule-approved-215500996.html
No comments:
Post a Comment